Drug Profile
Research programme: thrombin-activable factor X - Novo Nordisk
Alternative Names: Thrombin-activable factor XLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator C2X Pharma; INSERM
- Developer Novo Nordisk
- Class Proteins
- Mechanism of Action Blood coagulation factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia in Denmark (Parenteral)
- 17 Dec 2007 Preclinical trials in Haemophilia in Denmark (Parenteral)